Bibliography
- Hedgecoe A , MartinP: The drugs don‘t work: expectations and the shaping of pharmacogenetics.Soc. Stud. Sci.33(3) , 327–364 (2003).
- Lindpaintner K : Pharmacogenetics and the future of medical practice.J. Mol. Med.81 , 141–153 (2003).
- Webster A , MartinP, LewisG, SmartA: Integrating pharmacogenetics into society: in search of a model.Nat. Rev. Genet.5 , 663–669 (2004).
- Watson EK , ShickleD, QureshiN, EmeryJ, AustokerJ: The “new” genetics and primary care: general paractitioners‘ views on their role and their educational needs.Fam. Pract.16 , 420–425 (1999).
- Weinshilboum R , WangL: Pharmacogenomics: bench to bedside.Nat. Rev. Drug Discov.3 , 739–748 (2004).
- Buchanan A , CalifanoA, KahnJ, McPherson E, Robertson J, Brody B: Pharmacogenetics: ethical and regulatory issues in research and clinical practice. Report of the consortium on pharmacogenetics. Findings and recommendations, 10–11 (2002).
- Halpern SA : Lesser Harms: the Morality of Risk in Medical Research. University of Chicago Press, IL, USA (2004).
- Poirier J , DelisleMC, AubertI et al.: Apolipoprotein E allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA92 , 12260–12264 (1995).
- Lau KF , SakulH: Pharmacogenomics.Annu. Rep. Med. Chem.35 , 261–269 (2000).
- Steimer W , PotterJ: Pharmacogenetic screening and therapeutic drugs.Clin. Chim. Acta315 , 137–155 (2002).
- Crentsil V : The pharmacogenomics of Alzheimer‘s disease.Ageing Res. Rev.3 , 153–169 (2004).
- Hedgecoe A : Pharmacogenetics as alien science: Alzheimer‘s, core sets, and expectations.Soc. Stud. Sci.36(5) , 723–752 (2006).
- Winblad B , EngedalK, SoininenH et al.: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology57 , 489–495 (2001).
- Wilcock G , LilienfeldS, GaensE, Galantamine International-1 Study Group: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer‘s disease: multicentre randomised controlled trial. Br. Med. J.321 , 1–7 (2001).
- Hedgecoe A : The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge University Press, Cambridge, UK (2004).
- Chamberlain J , JoubertP: Opportunities and strategies for introducing pharmacogenetics into early drug development.Drug Discov. Today6(11) , 569–574 (2001).
- Roden D , GeorgeA: The genetic basis of variability in drug responses.Nat. Rev. Drug Discov.1 , 37–44 (2001).
- van der Zee M , HeleseA, de Boer A et al.: The interface between pharmacoepidemiology and pharmacogenetics. Eur. J. Pharmacol.410 , 121–130 (2000).
- Evans WE , JohnsonJA: Pharmacogenomics: the inherited basis for interindividual differences in drug response.Annu. Rev. Genomics Hum. Genet.2 , 9–39 (2001).
- Marshall A : Getting the right drug into the right patient.Nat. Biotechnol.15 , 1249–1252 (1997).
- Richard F , HelbecqueN, NeumanE et al.: APOE genotyping and response to drug treatment in Alzheimer‘s disease. Lancet349 , 539 (1997).
- Amouyel P : Pharmacogenomics and pharmacogenetics of neurodegenerative diseases: towards new targets.Pharmacogenomics3(1) , 1–3 (2002).
- Goldstein DB , TateSK, SisodiyaSM: Pharmacogenetics goes genomic.Nat. Rev. Genet.4 , 937–947 (2003).
- Hirschhorn JN , LohmuellerK, ByrneE et al.: A comprehensive review of genetic association studies. Genet. Med.4(2) , 45–61 (2002).
- Roses AD : Genome-based pharmacogenetics and the pharmaceutical industry.Nat. Rev. Drug Discov.1 , 541–549 (2002).
- Lindpaintner K : Pharmacogenetics and the future of medical practice.J. Mol. Med.81 , 141–153 (2003).
- Marteau TM , RobertsS, LaRusseS et al.: Predictive genetic testing for Alzheimer‘s disease: impact upon risk perception. Risk Anal.25(2) , 397–404 (2005).
- Roberts JS , BarberM, BrownT et al.: Who seeks genetic susceptibility testing for Alzheimer‘s disease? Findings from a multisite, randomized clinical trial. Genet. Med.6(4) , 197–203 (2004).
- Risner ME , SaundersAM, AltmanJFB et al.: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer‘s disease. Pharmacogenomics J.6(4) , 246–254 (2006).
Website
- Martin PA, Lewis G, Smart A, Webster A: False positive? Prospects for the clinical and commercial development of pharmacogenetics. University of Nottingham/University of York. www.nottingham.ac.uk/pgx